Paratek Pharmaceuticals Inc

Paratek Pharmaceuticals — Transcept Pharmaceuticals — Merger or Acquisition (July 2014)

13 slides from Paratek Pharmaceuticals's merger presentation, Jul 3, 2014

  1. Slide 1: Late Stage, Best-in-Class Antibiotics

    Late Stage, Best-in-Class Antibiotics 30 June 2014

  2. Slide 2: Forward Looking Statements / Risk Factors

    Institutional Only 2 Third-party information included herein has been obtained from sources believed to be reliable, but the accuracy or completeness of such information is not guaranteed by, and should not be construed as a representation by, Ladenburg Thalmann & Co. Inc. or the Company. The inform

  3. Slide 3: Additional Information about the Merger and Where to Find It

    Institutional Only 3 Additional Information about the Merger and Where to Find It In connection with a proposed merger, Transcept Pharmaceuticals, Inc., or Transcept, and Paratek intend to file relevant materials with the Securities and Exchange Commission, or the SEC, including a registration state

  4. Slide 4: Investment Highlights

    Institutional Only • Omadacycline: - 2 SPA agreements in place with FDA • ABSSSI & CABP phase 3 programs: commence 1H 2015 • Expedited FDA review through QIDP designation • ABSSSI & CABP indications at 2018 launch - cUTI phase 2 program to commence in 2H 2015 - Commercial scale-ready oral tablet plu

  5. Slide 5: Problem: Resistant Bacteria

    Institutional Only Problem: Resistant Bacteria 5 What is Needed?  Oral and IV formulations  Broad-spectrum Monotherapy  “Worry-free” safety & tolerability Omadacycline

  6. Slide 6: Omadacycline Opportunity: Addressing a Large Market Opportunity

    Institutional Only Omadacycline Opportunity: Addressing a Large Market Opportunity with an Oral and IV Antibiotic for Serious Community-Acquired Infections Antibiotic Inventor Form Indications Peak Year Sales Levaquin (J&J) Pharma Oral & IV Skin, Respiratory Tract, UTI $3.2 B Augmentin (GSK) Pharma

  7. Slide 7: Management: Proven Team Has Delivered Major Antibiotic Drugs to the Market

    Institutional Only Michael F. Bigham CEO Evan Loh, MD President & CMO Led Tygacil development Dennis P. Molnar SVP Beverly A. Armstrong VP, General Counsel and CCO Kathryn M. Boxmeyer VP, CFO and Treasurer Sean M. Johnston, PhD VP, Manufacturing S. Ken Tanaka, PhD VP, Research and Development Develo

  8. Slide 8: Paratek's Late-Stage Pipeline

    Institutional Only Paratek’s Late-Stage Pipeline Product Candidate Research Preclinical Phase 1 Phase 2 Phase 3 Commercial Rights Omadacycline(4) Sarecycline (WC 3035) ABSSSI(1) (Oral & IV) – FDA QIDP status CABP(2) (Oral & IV) – FDA QIDP status UTI(3) (Oral & IV) – FDA QIDP status Acne (oral) Rosac

  9. Slide 9: Omadacycline Compared to Linezolid in cSSSI Trials

    Institutional Only Omadacycline Compared to Linezolid in cSSSI Trials: Comparable Clinical Response Rates(1) Population(2) Clinical Success Rate(3) Omadacycline Linezolid Intent to Treat (ITT) 87.2% (156/179) 81.1% (146/180) Clinically Evaluable (CE) 97.5% (156/160) 94.2% (146/155) 9 (1) The table s

  10. Slide 10: Omadacycline: Minimal Safety & Tolerability Concerns for Physicians & Patients

    Institutional Only Omadacycline: Minimal Safety & Tolerability Concerns for Physicians & Patients • Over 700 human subject-exposures to omadacycline • TQTc(1) study completed; no hERG channel effects • No metabolites • No drug-drug interactions predicted • No GI side-effects predicted with commercia

  11. Slide 11: Phase 3 Omadacycline Registration Trial Designs: ABSSSI and CABP

    Institutional Only d3 – 5 d5-14 (1) S. aureus coverage added (Linezolid to moxifloxacin and placebo to Omadacycline) at investigator’s discretion. (2) TOC endpoint = Primary endpoint for EMA guidance Omadacycline(3) IV Omadacycline Oral Linezolid IV Early Response Linezolid Oral End of Treatment d1

  12. Slide 12: Unmet Need for Oral Antibiotic Treatment of cUTI

    Institutional Only Unmet Need for Oral Antibiotic Treatment of cUTI* *Medacorp survey 1Q 2013 • No effective oral antibiotic options for resistant E. coli, the predominant causative bacteria in cUTI • 97.1% of surveyed physicians believe that their patients with resistant E. coli could benefit from

  13. Slide 13: Investment Highlights

    Institutional Only • Omadacycline: - 2 SPA agreements in place with FDA • ABSSSI & CABP phase 3 programs: commence 1H 2015 • Expedited FDA review through QIDP designation • ABSSSI & CABP indications at 2018 launch - cUTI phase 2 program to commence in 2H 2015 - Commercial scale-ready oral tablet plu

Transcept Pharmaceuticals — Merger or Acquisition (July 2014) on 6ix